Safety Tolerability and Pharmacokinetics of SCTA01 an Anti-SARS-CoV-2 Monoclonal Antibody in Healthy Chinese Subjects

STATUS

Recruiting
participants needed

33
sponsor

Sinocelltech Ltd.

Updated on 19 February 2024

See if I qualify

Summary

Show definitions

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.

Description

This is a Phase 1, First-in-Human, Randomized, Double-blinded, Placebo-Controlled, Single Ascending Dose Study of SCTA01(Anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.

Dose escalation will be guided by a safety review of clinical signs and symptoms, adverse events (AEs), and laboratory results of the prior dose cohort.

An Interim analysis will be performed after Day 28 post-dose for the last dose cohort for review.

Details

Condition	Coronavirus Disease 2019
Age	18years - 100years
Treatment	Placebo, SCTA01
Clinical Study Identifier	NCT04483375
Sponsor	Sinocelltech Ltd.
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Able to provide written informed consent
	Males or females. Aged 18 years old
	Body mass index (BMI) between 18.0 and 26.0 kg/m2
	Normal or abnormal but non-clinical significant physical examination, vital signs, 12-ECG and chest CT, etc
	No plan of pregnancy and being willing to use effective contraceptive measures (including partner) from informed consent to 6 months after administration of SCTA01/placebo (abstinencesterilization operationcontraceptive barrieracyeterion , etc.)
Exclusion Criteria
	Having a history of severe allergy, such as severe allergic reactions, urticaria, angioedema
	Having one of the following evidence on SARS-CoV-2 infection(previous tests were accepted)
	SARS-CoV-2 positive: reverse transcription-polymerase chain reaction (RT-PCR) and/or next generation sequencing (NGS)
	Previous viral gene sequencing showed high homology with the known SARS-CoV-2
	Positive specific antibody IgM or IgG against serum SARS-CoV-2
	Having a history of severe allergies, such as severe allergic reactions, urticaria, angioedema
	Having active infection or fever before to enrollment( 37.3)
	Having primary disease in main organs, such as heart, lung, kidney, liver, nervous system, gastrointestinal system dysfunction, history of thrombocytopenia or abnormal bleeding
	Suffering from autoimmune diseases or a history of autoimmune diseases (such as systemic lupus erythematosus, thyroid Inflammation, vasculitis, etc.)
	Within 7 days prior to the first dose of SCTA01/placebo, subject has received any prescription drugs, non-prescription drugs, Chinese herbal medicines and health products
	Within 3 months prior to the first dose of SCTA01/placebo, subjects who participated in other clinical study, or remaining in the elimination period of the drug (within 5 half-lives) before treatment
	Within 30 days prior to the first dose of SCTA01/placebo, subjects who have received vaccine
	Within 3 months prior to the first dose of SCTA01/placebo, subjects who have received blood product treatment or blood donation and hemorrhage 400mL, or subjects who has a blood donation plan within 3 months after treatment
	Within 6 months prior to the first dose of SCTA01/placebo, subjects who have received major surgery, or has surgery plan during clinical trail
	Pregnant or lactating women or positive -HCG, has plan of pregnancy from informed consent signed to 6 months after administration of SCTA01/placebo
	Positive of anti-HIV, TP-Ab, anti-HCV, anti-HBV
	Having a history of epilepsy
	Having a history of malignancies
	Within 3 months prior to screening, sujects who have drunk more than 14 standard units (1 standard unit contains 14g alcohol, such as 360mL beer, 45mL spirits with 40% alcohol or 150mL wine), or positive of alcohol breath test
	Within 3 months prior to screening, subjects who smoked more than 5 cigarettes per day, do not accept smoking cessation during the study
	Having a history of drug addiction and drug abuse; or who have a positive urine test result for drug abuse; or cannot guarantee that they will not abuse drugs during the study
	Subjects who are not able to follow the plan to complete the study
	Subjects who are not considered suitable for the study by investigators

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Safety Tolerability and Pharmacokinetics of SCTA01 an Anti-SARS-CoV-2 Monoclonal Antibody in Healthy Chinese Subjects

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note

Safety Tolerability and Pharmacokinetics of SCTA01 an Anti-SARS-CoV-2 Monoclonal Antibody in Healthy Chinese Subjects

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Sign up as a volunteer to stay informed

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note